meta-analysis | Q815382 |
scholarly article | Q13442814 |
systematic review | Q1504425 |
review article | Q7318358 |
P819 | ADS bibcode | 2013PLoSO...868152P |
P356 | DOI | 10.1371/JOURNAL.PONE.0068152 |
P932 | PMC publication ID | 3707972 |
P698 | PubMed publication ID | 23874527 |
P5875 | ResearchGate publication ID | 250925812 |
P50 | author | Reto Nüesch | Q41653968 |
Thomas Reiberger | Q42987335 | ||
Deenan Pillay | Q57899870 | ||
Richard Gilson | Q62006744 | ||
Firouzé Bani-Sadr | Q88947273 | ||
Marina Nunez | Q89643739 | ||
David T Dunn | Q91490016 | ||
Christoph Stephan | Q96206968 | ||
Mamta K Jain | Q98936517 | ||
Marion G Peters | Q104074133 | ||
Stefan Mauss | Q114739524 | ||
Huw Price | Q117791924 | ||
Theodora de Vries-Sluijs | Q117792002 | ||
Noriyoshi Kuzushita | Q117792037 | ||
Lionel Tan | Q117792401 | ||
P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients | Q28375088 | ||
Predictors of loss of hepatitis B surface antigen in HIV-infected patients | Q33716290 | ||
Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data | Q33799094 | ||
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. | Q33968358 | ||
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. | Q34621209 | ||
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients | Q35200503 | ||
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients | Q37149701 | ||
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. | Q39375453 | ||
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains | Q39876916 | ||
In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents | Q40115548 | ||
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus | Q40262602 | ||
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection | Q41604155 | ||
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand | Q42909958 | ||
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus | Q42923518 | ||
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. | Q42989166 | ||
Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus | Q43906148 | ||
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort | Q43972819 | ||
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus | Q44583350 | ||
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine | Q45397952 | ||
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection | Q45398562 | ||
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study | Q45413375 | ||
Tenofovir for chronic hepatitis B virus infection in HIV-coinfected patients. | Q45417636 | ||
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus | Q45422795 | ||
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. | Q45423363 | ||
Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir. | Q46003766 | ||
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 | ||
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. | Q46243261 | ||
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand | Q46433832 | ||
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. | Q46644424 | ||
Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. | Q54571805 | ||
British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010 | Q57180947 | ||
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection | Q57271233 | ||
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study | Q58097173 | ||
Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV | Q58376622 | ||
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response | Q58646483 | ||
Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues | Q82451832 | ||
Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients | Q84293502 | ||
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir | Q84868978 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Hepatitis B virus | Q6844 |
hepatitis B | Q6853 | ||
adenine | Q15277 | ||
tenofovir | Q155954 | ||
human immunodeficiency virus infectious disease | Q18556697 | ||
coinfection | Q1243018 | ||
anti-HIV agents | Q50377208 | ||
organophosphonate | Q76636048 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | e68152 | |
P577 | publication date | 2013-07-10 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis | |
P478 | volume | 8 |